Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gram-Negative Bacterial Infections Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection

NCT00132457
View directory record Official record
Conditions
Chlamydia Infections
Interventions
Self-collected vaginal swab for chlamydia testing
Procedure
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years and older · Female only
Enrollment
1,830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
New Orleans, Louisiana • Jackson, Mississippi • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 6, 2026, 9:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reversal of Lipid-Induced Insulin Resistance

NCT02193295
View directory record Official record
Conditions
Insulin Resistance, NAFLD
Interventions
Caloric Restriction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2034
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 1 Interventional

Effects of Psilocybin in Post-Treatment Lyme Disease

NCT05305105
View directory record Official record
Conditions
Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 6, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

NCT00258882
View directory record Official record
Conditions
Pertussis
Interventions
Tetanus Toxoid, acellular pertussis, diphtheria toxoid
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
327,293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 6, 2026, 9:42 PM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Post Treatment Lyme Disease

NCT06915324
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Transcranial Direct Current Stimulation (tDCS), Cognitive training
Device · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

NCT00254995
View directory record Official record
Conditions
Meningitis, Meningococcal Disease
Interventions
None administered in this study
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
62,626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 6, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

Linezolid for Syphilis Pilot Study

NCT05548426
View directory record Official record
Conditions
Syphilis
Interventions
Group B, Linezolid 10d, Group A, Penicillin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Jackson, Mississippi • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed No phase listed Observational

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

NCT00573521
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 6, 2026, 9:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872
View directory record Official record
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
Interventions
Miransertib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

NCT02100631
View directory record Official record
Conditions
Cholera
Interventions
PXVX0200, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
46 Years to 64 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
16
States / cities
Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Not applicable Interventional

Self-Monitoring Shopping Intervention

NCT04020302
View directory record Official record
Conditions
Intellectual Disability, Down Syndrome
Interventions
Self-monitoring shopping intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Hillsborough, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

NCT01382095
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

NCT00097396
View directory record Official record
Conditions
Pneumonic Plague, Preventive Therapy
Interventions
rF1V vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 6, 2026, 9:42 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study of a Single-Use, Point-of-Care Molecular Diagnostic Device for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) Utilizing Vaginal Swabs

NCT03596151
View directory record Official record
Conditions
Chlamydial Infection, Gonorrhoea, Trichomoniasis
Interventions
Click Device
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 99 Years · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 6, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes

NCT00958139
View directory record Official record
Conditions
Lyme Disease
Interventions
Permethrin, Placebo
Other
Lead sponsor
University of Minnesota
Other
Eligibility
14 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rice Lake, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Not applicable Interventional Results available

Feasibility of Teleyoga for Treatment of Lyme Disease

NCT04867473
View directory record Official record
Conditions
Lyme Disease
Interventions
Teleyoga
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654
View directory record Official record
Conditions
Typhoid Fever
Interventions
Ty800 (Salmonella typhi) Oral Vaccine
Biological
Lead sponsor
Avant Immunotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
View directory record Official record
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed No phase listed Observational

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

NCT00414362
View directory record Official record
Conditions
Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)

NCT04302675
View directory record Official record
Conditions
Maternal Immunization
Interventions
Prevention, Maternal Immunization
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 6, 2026, 9:42 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Azithromycin in Control of Trachoma II

NCT00286026
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 3 Interventional

Study and Treatment of Post Lyme Disease (STOP-LD)

NCT00000937
View directory record Official record
Conditions
Lyme Disease
Interventions
Antibiotics
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine

NCT01442675
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 55 Years
Enrollment
834 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
15
States / cities
Little Rock, Arkansas • San Diego, California • Bardstown, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 6, 2026, 9:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM

NCT00187902
View directory record Official record
Conditions
Sexually Transmitted Diseases, Chlamydia, Gonorrhea
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 6, 2026, 9:42 PM EDT